A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 3, 1998, Pages 770-774

  Berndt, Ilona ^a   Reuter, Marlene ^a   Saller, B ^b   Frank Raue, Karin ^c   Groth, P ^d   Grussendorf M ^e   Raue, F ^c   Ritter, M M ^f   Hoppner W ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Endokrinologische Praxisgemeinschaft   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e Endokrinologische Praxisgemeinschaft   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; ARTICLE; CODON; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; AMINO ACID SEQUENCE; BASE SEQUENCE; CARCINOMA, MEDULLARY; CODON; DNA, NEOPLASM; DROSOPHILA PROTEINS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PEDIGREE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 0031765304     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.3.770     Document Type: Article

References (20)

1. Donis-Keller H, Dou S, Chi D, et al. 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 2:851-856.
2. Mulligan LM, Kwok JB, Healey CS, et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 363:458-460.
3. Eng C, Clayton D, Schuffenecker I, et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA. 276:1575-1579.
4. Eng C, Smith DP, Mulligan LM, et al. 1994, A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene. 6:70-74.
5. Bolino A, Schuffenecker I, Luo Y, et al. 1995 RET mutations in exons 13 and 14 of FMTC patients. Oncogene. 10:2415-2419.
6. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. 1988 Cloning and expression of the ret proto-oncogene encoding tyrosine kinase with two potential transmembrane domains. Oncogene. 3:571-578.
7. Pachnis V, Mankoo B, Constantini F. 1993 Expression of the c-ret proto-oncogene during mouse embryogenesis. Development. 119:1005-1017.
8. Miya A, Yamamoto M, Morimoto H, et al. 1992 Expression of the RET proto-oncogene in human medullary thyroid carcinomas and pheochromocytomas of MEN 2A. Henry Ford Hosp Med J. 40:215-219.
9. Trupp M, Arena E, Fainzilber M, et al. 1996 Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature. 381:785-789.
10. Jing S, Wen D, Yu Y, et al. 1996 GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell. 85:1113-1124.
11. Treanor JJ, Goodman L, de Sauvage F, et al. 1996 Characterization of a multicomponent receptor for GDNF. Nature. 382:80-83.
12. Frank-Raue K, Höppner W, Frilling A, et al. 1996 Mutations of the ret proto-oncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab. 81:1780-1783.
13. Hofstra RMW, Landsvater RM, Ceccherini I, et al. 1994, A mutation in the RET proto-oncogene associated with endocrine neoplasia type 2B and sporadic thyroid carcinoma. Nature 367:375-376.
14. Lips CJM, Landsvater RM, Höppener WM, et al. 1994, Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 331:828-835.
15. Eng C, Smith PC, Mulligan LM, et al. 1995 A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and a family with FMTC. Oncogene 10:509-513.
16. Höppner W, Dralle H, Brabant G. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. Hum Mutat. In press.
17. Höppner W, Ritter MM. 1996, A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet. 6:587-590.
18. Komminoth P, Feurer SM, Seelentag WKF, Roth J, Heitz PU. 1996 Analysis of RET proto-oncogene mutations in Swiss families with multiple endocrine neoplasia type 2. In: Müller Hj, Scott RJ, Weber W, eds. Hereditary Cancer. 2nd Int. Res. Conf. on Familial Cancer, Basel, 1995. Basel: Karger; pp. 108-118.
19. Liu X, Verga CQ, Decker RA, et al. 1996, Oncogenic ret receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem. 271:5309-5312.
20. Asai N, Murakami H, Iwashita T, Takahashi M. 1997, A mutation at tyrosine 1062 in MEN 2A-Ret and MEN 2B-Ret impairs their transforming activity and association with the Shc adaptor proteins. J Biol Chem. 271:17644-17649.